Antibody Drug Conjugates Market Expected to Reach $3,198 Million by 2023

Antibody drug conjugates is an unconventional and efficient anti-cancer drug. Continuous increase in demand for efficient and targeted cancer therapy medications are expected to drive the antibody drug conjugate market.

Antibody Drug Conjugates Market are highly effective biopharmaceutical medications designed as a targeted therapy for cancer treatment. ADC’s are designed to eliminate cancer cells only without harming the normal cells. This is a major advantage of ADC’s as the unharmed healthy cells enable patients to recover faster. The antibody drug conjugates market was valued at $1,387 million in 2016, and is estimated to reach $3,198 million by 2023, registering a CAGR of 12.9% from 2017 to 2023.

Download PDF Sample: https://www.alliedmarketresearch.com/request-sample/1467

Antibody drug conjugates are highly powerful biopharmaceutical medications prepared by integrating two principles i.e. a cell killing highly powerful active pharmaceutical ingredient (HPAPI) and explicit nature of monoclonal antibodies. They are highly effective anticancer drugs targeting only cancer infected cells thus, leaving healthy uninfected cell intact facilitating quick recovery of cancer patients.

Increase in prevalence of cancer and rise in demand for efficient and cost-effective cancer treatments drive the market. Moreover, extensive research on drug development and large number of pipeline drugs for ADCs present in different stages of approvals are expected to boost the market growth. Approval of pipelined drugs increase the number of available ADC products, cumulatively spurring market turnover of ADCs. However, strict regulation set by regulating authorities for approval of ADCs and complications associated with drug development impedes the growth of antibody drug conjugates market. Growth in adoption of ADCs over conventional cancer treatments and rapidly developing market in Asia-Pacific & LAMEA create opportunities for market players.

North America holds the highest market share in 2016 owing to high prevalence of cancer in the region and modern healthcare facilities for employment of novel therapeutic procedures. Moreover, adoption of experimental medicines and growth in awareness about antibody drug conjugates in the region is expected to boost the North American market. However, Asia-Pacific region is expected to grow at the highest CAGR during the forecast period considering, high reported prevalence of cancer constituting a large patient pool.

Key Findings of the Antibody Drug Conjugates Market:

- The Kadcyla segment is projected to grow at the highest CAGR in 2016 during the analysis period.
- Breast cancer segment generated the highest revenue in 2016 and is expected to continue its dominance in future.
- North America dominated the market in 2016
- China is expected to grow at the highest CAGR in 2016, in Asia-Pacific.

Get More Information: https://www.alliedmarketresearch.com/antibody-drug-caonjugate-market

The key companies profiled in the report include F. Hoffman-La Roche Ltd., ImmunoGen, Inc., Bayer AG, Novartis AG, Immunomedics, Inc., Agensys, Inc., Takeda Pharmaceutical Company Limited, Seattle Genetics, Inc., Concortis Biotherapeutics, and NBE-Therapeutics.

About Us:

Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
Shriram Dighe
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.